Published in Crit Rev Oncog on January 01, 2012
Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle (2014) 2.12
Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci (2012) 1.46
Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta (2012) 1.16
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer (2014) 1.01
Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem (2013) 1.00
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta (2014) 0.98
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
K(+) channels and cell cycle progression in tumor cells. Front Physiol (2013) 0.87
Combination of low concentration of (-)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int J Mol Sci (2013) 0.86
p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer. J Cancer Res Clin Oncol (2013) 0.81
Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep (2015) 0.79
Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax. Cell Cycle (2014) 0.78
CARP is a potential tumor suppressor in gastric carcinoma and a single-nucleotide polymorphism in CARP gene might increase the risk of gastric carcinoma. PLoS One (2014) 0.76
A Strategy for Direct Chemical Activation of the Retinoblastoma Protein. ACS Chem Biol (2016) 0.75
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer (2016) 0.75
Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb. Cancer Biol Ther (2016) 0.75
Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Front Genet (2016) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One (2007) 2.26
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol (2009) 2.21
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell (2012) 1.91
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer (2010) 1.89
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol (2002) 1.78
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer (2005) 1.73
Cyclins and breast cancer. J Mammary Gland Biol Neoplasia (2004) 1.73
Cell cycle control in breast cancer cells. J Cell Biochem (2006) 1.68
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res (2010) 1.62
Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int (2013) 1.55
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res (2005) 1.48
Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer (2003) 1.47
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res (2003) 1.43
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A (2005) 1.41
The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle (2007) 1.36
EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem (2002) 1.34
Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 1.32
Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem (2005) 1.32
The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res (2005) 1.32
Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res (2008) 1.30
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
Edd, the murine hyperplastic disc gene, is essential for yolk sac vascularization and chorioallantoic fusion. Mol Cell Biol (2004) 1.28
Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol (2008) 1.28
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology (2009) 1.27
Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div (2010) 1.27
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene (2002) 1.26
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One (2009) 1.25
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res (2011) 1.25
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene (2003) 1.23
c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol (2006) 1.22
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res (2002) 1.21
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res (2004) 1.21
EDD mediates DNA damage-induced activation of CHK2. J Biol Chem (2006) 1.21
Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene (2005) 1.20
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res (2011) 1.18
Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol (2011) 1.17
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol (2012) 1.16
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol (2009) 1.16
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res (2011) 1.14
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res (2007) 1.14
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res (2004) 1.13
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res (2004) 1.13
Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer (2005) 1.12
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle (2010) 1.10
Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle (2013) 1.09
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res (2013) 1.08
Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One (2011) 1.07
Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res (2002) 1.07
Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer (2011) 1.07
Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate (2004) 1.06
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene (2003) 1.06
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate (2008) 1.05
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05